|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
WLY012323063 |
| 003 |
DE-627 |
| 005 |
20230308000031.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
230220s2019 xx |||||o 00| ||und c |
| 024 |
7 |
|
|a 10.1111/pim.12616
|2 doi
|
| 028 |
5 |
2 |
|a PIM_PIM12616.xml
|
| 035 |
|
|
|a (DE-627)WLY012323063
|
| 035 |
|
|
|a (WILEY)PIM12616
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rda
|
| 082 |
0 |
4 |
|a 590
|q ASE
|
| 084 |
|
|
|a 42.00
|2 bkl
|
| 100 |
1 |
|
|a Zamora, Vega
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Induction of tolerogenic properties by Anisakis larval antigens on murine dendritic cells
|
| 264 |
|
1 |
|c 2019
|
| 300 |
|
|
|a 6
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Copyright © 2019 John Wiley & Sons Ltd
|
| 520 |
|
|
|a Summary Aims The objective of this work is to investigate whether Anisakis simplex larval antigens present immunomodulatory properties by the induction of tolerogenic dendritic cells ( DC s) from two strains of mice ( BALB/c and C57 BL/6J). Methods and Results We used mouse bone marrow‐derived DC s. We determined their antigen‐presenting ability by expression of membrane markers ( MHC I and MHC II, CD80, CD86) and intracellular expression levels of IL‐10 and IL‐12 cytokines. We also analysed whether stimulation with A simplex larval antigens is enhanced by the co‐administration of the TLR4 and TLR9 agonists [ LPS E coli026B6 and CpG ( ODN1826), respectively]. Two differential types of responses were found in the two mouse strains studied: the BALB/c strain showed an acute and inflammatory response, whereas the C57 BL/6J mice developed a more discrete and resistant response. This suggests the coexistence of two opposing responses generated by A simplex larval antigens and confirms that the host genetic basis plays a role in the development of a Th2 or T reg response. Conclusion The study of the mechanisms by which Anisakis manipulates the immune response through anti‐inflammatory molecules is of interest not only for the direct application on the development of anthelmintic strategies, but also for the development of new anti‐inflammatory products.
|
| 700 |
1 |
|
|a Rodero, Marta
|4 aut
|
| 700 |
1 |
|
|a Andreu‐Ballester, Juan Carlos
|4 aut
|
| 700 |
1 |
|
|a Mendez, Susana
|4 aut
|
| 700 |
1 |
|
|a Cuéllar, Carmen
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Parasite Immunology
|g 41(2019), 4
|w (DE-627)WLY012322709
|x 13653024
|7 nnns
|
| 773 |
1 |
8 |
|g volume:41
|g year:2019
|g number:4
|g extent:6
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_WLY
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_21
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_110
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_206
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_618
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2009
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 912 |
|
|
|a GBV_ILN_2035
|
| 912 |
|
|
|a GBV_ILN_2105
|
| 936 |
b |
k |
|a 42.00
|q ASE
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 41
|j 2019
|e 4
|g 6
|